Ironwood Pharmaceuticals (Ironwood Pharmaceuticals) Price-to-Tangible-Book : (As of Apr. 25, 2024)

View and export this data going back to 2010. Start your Free Trial

What is Ironwood Pharmaceuticals Price-to-Tangible-Book?

As of today (2024-04-25), Ironwood Pharmaceuticals's share price is $8.10. Ironwood Pharmaceuticals's Tangible Book per Share of Dec. 2023 for the quarter that ended in Dec. 2023 was $-2.24. Hence, Ironwood Pharmaceuticals's Price to Tangible Book Ratio of today is .

The historical rank and industry rank for Ironwood Pharmaceuticals's Price-to-Tangible-Book or its related term are showing as below:

During the past 13 years, Ironwood Pharmaceuticals's highest Price to Tangible Book Ratio was 29.21. The lowest was 2.93. And the median was 14.61.

IRWD's Price-to-Tangible-Book is not ranked ^*
in the Drug Manufacturers industry.
Industry Median: 2.32
* Ranked among companies with meaningful Price-to-Tangible-Book only.

A closely related ratio is called PB Ratio. As of today, Ironwood Pharmaceuticals's share price is $8.10. Ironwood Pharmaceuticals's Book Value per Sharefor the quarter that ended in Dec. 2023 was $-2.22. Hence, Ironwood Pharmaceuticals's P/B Ratio of today is .

Ironwood Pharmaceuticals Price-to-Tangible-Book Historical Data

The historical data trend for Ironwood Pharmaceuticals's Price-to-Tangible-Book can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Ironwood Pharmaceuticals Price-to-Tangible-Book Chart

Ironwood Pharmaceuticals Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Price-to-Tangible-Book

Get a 7-Day Free Trial

29.21

3.12

2.93

Ironwood Pharmaceuticals Quarterly Data
	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23
Price-to-Tangible-Book	Get a 7-Day Free Trial															2.93	2.31	-	-	-

Competitive Comparison of Ironwood Pharmaceuticals's Price-to-Tangible-Book

For the Drug Manufacturers - Specialty & Generic subindustry, Ironwood Pharmaceuticals's Price-to-Tangible-Book, along with its competitors' market caps and Price-to-Tangible-Book data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Ironwood Pharmaceuticals's Price-to-Tangible-Book Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Ironwood Pharmaceuticals's Price-to-Tangible-Book distribution charts can be found below:

* The bar in red indicates where Ironwood Pharmaceuticals's Price-to-Tangible-Book falls into.

Ironwood Pharmaceuticals Price-to-Tangible-Book Calculation

Ironwood Pharmaceuticals's price-to-tangible-book ratio for today is calculated as:

Price to Tangible Book	=	Share Price	/	Tangible Book per Share (Q: Dec. 2023 )
	=	8.10	/	-2.238
	=

It can also be calculated from the numbers for the whole company:

Price to Tangible Book	=	Market Cap	/	Tangible Equity
	=	Market Cap	/	(Total Stockholders Equity	-	Preferred Stock	-	Intangible Assets)

A closely related ratio is called PB Ratio. The difference between Price-to-Tangible-Book Ratio and PB Ratio is that book value other than intangibles are used in the calculation.

Be Aware

Some businesses have very light assets, such as software companies or insurance agencies. The Price-to-Book Ratio does not work well for these companies. Some companies even have negative equity, so the Price-to-Book Ratio cannot be applied to them.

Ironwood Pharmaceuticals Price-to-Tangible-Book Related Terms

Thank you for viewing the detailed overview of Ironwood Pharmaceuticals's Price-to-Tangible-Book provided by GuruFocus.com. Please click on the following links to see related term pages.

Ironwood Pharmaceuticals (Ironwood Pharmaceuticals) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Ironwood Pharmaceuticals Inc (NAS:IRWD) » Definitions » Price-to-Tangible-Book

Comparable Companies

Traded in Other Exchanges

I76:Germany I76:Germany

Address

100 Summer Street, Suite 2300, Boston, MA, USA, 02110

Website

https://www.ironwoodpharma.com

Ironwood Pharmaceuticals is a specialty and generic drug manufacturing company that operates a human therapeutics segment. The company is focused on advancing innovative product opportunities in areas of large unmet need, including irritable bowel syndrome with constipation, chronic idiopathic constipation, hyperuricemia associated with uncontrolled gout, uncontrolled gastroesophageal reflux disease, and vascular and fibrotic diseases. The company considers collaborative licenses, commercial agreements, and acquisition investment to be potential components of its operational growth strategy for expanding its research, development, manufacturing, and marketing capabilities.

Executives

Marla L Kessler	director	C/O IRONWOOD PHARMACEUTICALS, INC., 100 SUMMER STREET, SUITE 2300, BOSTON MA 02110
Andrew Davis	officer: SVP, Chief Business Officer	100 SUMMER STREET, SUITE 2300, BOSTON MA 02110
Sravan Kumar Emany	officer: SVP, Chief Financial Officer	100 SUMMER ST, SUITE 2300, BOSTON MA 02109
Ronald Silver	officer: Principal Accounting Officer	100 SUMMER STREET, SUITE 2300, BOSTON MA 02110
Minardo John	officer: Chief Legal Officer	100 SUMMER STREET, SUITE 2300, BOSTON MA 02110
Thomas A Mccourt	officer: Chief Commercial Officer	C/O IRONWOOD PHARMACEUTICALS, INC., 100 SUMMER STREET, SUITE 2300, BOSTON MA 02110
Michael Shetzline	officer: CMO,SVP,Head-Res&Drug	100 SUMMER STREET, SUITE 2300, BOSTON MA 02110
Jason Rickard	officer: SVP, Chief Operating Officer	100 SUMMER STREET, SUITE 2300, BOSTON MA 02110
Mark G Currie	officer: Chief Scientific Officer	C/O CYCLERION THERAPEUTICS, INC., 301 BINNEY STREET, CAMBRIDGE MA 02142
Julie Mchugh	director	C/O IRONWOOD PHARMACEUTICALS, INC., 100 SUMMER STREET, SUITE 2300, BOSTON MA 02110
Sarissa Capital Management Lp	10 percent owner	660 STEAMBOAT ROAD, GREENWICH CT 06830
Alexander J Denner	director	C/O SARISSA CAPITAL MANAGEMENT LP, 660 STEAMBOAT ROAD, 3RD FLOOR, GREENWICH CT 06830
Edward P Owens	director	C/O IRONWOOD PHARMACEUTICALS, INC., 100 SUMMER STREET, SUITE 2300, BOSTON MA 02110
Gina Consylman	officer: Chief Accounting Officer	C/O IRONWOOD PHARMACEUTICALS, INC., 100 SUMMER STREET, SUITE 2300, BOSTON MA 02110
Kilroy Conor	officer: SVP, GC & Secretary	100 SUMMER STREET, SUITE 2300, BOSTON MA 02110